Omeros/$OMER
1D1W1MYTD1Y5YMAX
Capital at risk
About Omeros
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
- Ticker
- $OMER
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 175
- Headquarters
- Seattle, United States
- Website
- www.omeros.com
Omeros Metrics
BasicAdvanced
$1.3B
11.11
$1.57
2.54
-
Price and volume
Market cap
$1.3B
Beta
2.54
52-week high
$19.65
52-week low
$3.94
Average daily volume
2.1M
Financial strength
Current ratio
1.951
Quick ratio
1.614
Long term debt to equity
-4.626
Total debt to equity
-5.781
Interest coverage (TTM)
-3.25%
Profitability
EBITDA (TTM)
-71.913
Gross margin (TTM)
38.34%
Net profit margin (TTM)
324.88%
Operating margin (TTM)
-189.53%
Effective tax rate (TTM)
1.77%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-18.68%
Return on equity (TTM)
-83.23%
Valuation
Price to earnings (TTM)
11.112
Price to revenue (TTM)
31.974
Price to book
-24.51
Price to tangible book (TTM)
-24.51
Price to free cash flow (TTM)
7.173
Free cash flow yield (TTM)
13.94%
Free cash flow per share (TTM)
2.434
Growth
Earnings per share change (TTM)
-174.52%
10-year revenue growth (CAGR)
3.45%
3-year earnings per share growth (CAGR)
34.79%
10-year earnings per share growth (CAGR)
-1.89%
What the Analysts think about Omeros
Analyst ratings (Buy, Hold, Sell) for Omeros stock.
Analyst projections of the future price of Omeros stock.
Bulls say / Bears say
YARTEMLEA generated net product revenue of $28.5 million in Q2 2026, a 188% sequential increase from $9.9 million in Q1, driving Omeros to operating break-even for the first time. (Nasdaq)
The November 2025 asset sale and licensing agreement of zaltenibart to Novo Nordisk reduced OMS906-related R&D expense, contributing to a non-GAAP adjusted net loss of $17.1 million in Q1 2026, down from heavier losses in prior periods. (Omeros Q1 2026 Release)
In April 2026, CMS assigned a permanent Healthcare Common Procedure Coding System J-code for YARTEMLEA (effective July 1, 2026) and recommended NTAP status (effective October 1, 2026), enhancing hospital reimbursement and supporting broader patient access. (Omeros Q1 2026 Release)
In June 2026, the EMA’s Committee for Medicinal Products for Human Use issued a negative opinion on Omeros’s EU marketing authorization application for narsoplimab, delaying potential approval and limiting a key growth market. (Nasdaq)
Cash and short-term investments declined to $132.0 million at June 30, 2026, down from $135.3 million at March 31, 2026, potentially necessitating additional financing as pipeline and commercial activities scale. (Omeros Q2 2026 Release & Omeros Q1 2026 Release)
Second-quarter GAAP net income of $13.2 million was driven by an $11.5 million non-cash mark-to-market gain on embedded derivatives, with non-GAAP adjusted net income only $1.8 million, underscoring limited underlying profitability. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 23 Aug 2026.
Omeros Financial Performance
Revenues and expenses
Omeros Earnings Performance
Company profitability
Upcoming events
No upcoming events
Omeros News
AllArticlesVideos
Funds containing Omeros
AllUSDGBPEUR
Fund name | Fund size | $OMER weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.06% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.05% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.